SK Bioscience Co Ltd
KRX:302440
SK Bioscience Co Ltd
KRX:302440
Price:
40 450
KRW
-2.76%
Market Closed
Market Cap:
3.2T
KRW
Income Statement
Earnings Waterfall
SK Bioscience Co Ltd
SK Bioscience Co Ltd
|
Revenue
|
267.5B
KRW
|
|
Cost of Revenue
|
-236.6B
KRW
|
|
Gross Profit
|
31B
KRW
|
|
Operating Expenses
|
-169.4B
KRW
|
|
Operating Income
|
-138.4B
KRW
|
|
Other Expenses
|
88.3B
KRW
|
|
Net Income
|
-50.1B
KRW
|
Income Statement
SK Bioscience Co Ltd
SK Bioscience Co Ltd
Currency: KRW
Millions
TTM
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Revenue |
223 385
N/A
|
225 611
+1%
|
338 321
+50%
|
423 012
+25%
|
545 152
+29%
|
929 001
+70%
|
903 382
-3%
|
897 059
-1%
|
767 283
-14%
|
456 726
-40%
|
390 231
-15%
|
278 429
-29%
|
419 202
+51%
|
369 506
-12%
|
371 179
+0%
|
371 479
+0%
|
201 300
-46%
|
267 545
+33%
|
|
| Gross Profit | |||||||||||||||||||
| Cost of Revenue |
(128 874)
|
(130 269)
|
(169 577)
|
(184 162)
|
(226 643)
|
(358 718)
|
(358 693)
|
(349 263)
|
(295 051)
|
(217 115)
|
(197 543)
|
(165 406)
|
(256 486)
|
(227 263)
|
(224 425)
|
(213 071)
|
(146 547)
|
(236 569)
|
|
| Gross Profit |
94 511
N/A
|
95 342
+1%
|
168 744
+77%
|
238 850
+42%
|
318 509
+33%
|
570 283
+79%
|
544 689
-4%
|
547 796
+1%
|
472 232
-14%
|
239 611
-49%
|
192 688
-20%
|
113 023
-41%
|
162 716
+44%
|
142 243
-13%
|
146 754
+3%
|
158 408
+8%
|
54 753
-65%
|
30 976
-43%
|
|
| Operating Income | |||||||||||||||||||
| Operating Expenses |
(53 519)
|
(57 631)
|
(77 318)
|
(71 595)
|
(87 321)
|
(96 063)
|
(100 432)
|
(108 505)
|
(111 988)
|
(124 597)
|
(130 615)
|
(147 449)
|
(157 563)
|
(154 231)
|
(158 809)
|
(155 093)
|
(151 989)
|
(169 407)
|
|
| Selling, General & Administrative |
(28 079)
|
(30 286)
|
(40 409)
|
(36 701)
|
(43 030)
|
(46 656)
|
(47 511)
|
(51 723)
|
(52 944)
|
(62 773)
|
(64 522)
|
(65 823)
|
(67 957)
|
(62 648)
|
(64 467)
|
(65 429)
|
(68 270)
|
(89 145)
|
|
| Research & Development |
(24 227)
|
(24 645)
|
(35 138)
|
(33 275)
|
(42 391)
|
(47 250)
|
(50 418)
|
(53 803)
|
(55 621)
|
(57 960)
|
(61 780)
|
(76 951)
|
(84 389)
|
(85 743)
|
(86 878)
|
(81 769)
|
(75 545)
|
(71 353)
|
|
| Depreciation & Amortization |
(1 211)
|
(2 701)
|
(1 779)
|
(1 628)
|
(1 908)
|
(2 157)
|
(2 503)
|
(2 978)
|
(3 423)
|
(3 865)
|
(4 313)
|
(4 675)
|
(5 217)
|
(5 839)
|
(6 310)
|
(6 741)
|
(7 020)
|
(8 910)
|
|
| Other Operating Expenses |
0
|
0
|
9
|
9
|
9
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1 154)
|
(1 154)
|
(1 154)
|
0
|
|
| Operating Income |
40 993
N/A
|
37 710
-8%
|
91 426
+142%
|
167 256
+83%
|
231 188
+38%
|
474 220
+105%
|
444 257
-6%
|
439 292
-1%
|
360 244
-18%
|
115 014
-68%
|
62 073
-46%
|
(34 426)
N/A
|
5 153
N/A
|
(11 988)
N/A
|
(12 055)
-1%
|
3 315
N/A
|
(97 236)
N/A
|
(138 431)
-42%
|
|
| Pre-Tax Income | |||||||||||||||||||
| Interest Income Expense |
(2 685)
|
(2 251)
|
(997)
|
388
|
(3 591)
|
(5 401)
|
2 587
|
(1 791)
|
5 089
|
31 166
|
26 979
|
38 246
|
33 986
|
19 311
|
22 225
|
19 925
|
31 839
|
23 833
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1 154)
|
0
|
0
|
0
|
15 410
|
|
| Gain/Loss on Disposition of Assets |
(5)
|
236
|
254
|
19
|
21
|
24
|
(112)
|
(159)
|
(355)
|
(435)
|
(324)
|
(286)
|
(97)
|
(68)
|
(66)
|
(113)
|
(110)
|
14 259
|
|
| Total Other Income |
459
|
1 597
|
1 652
|
3 905
|
2 518
|
2 286
|
2 111
|
(1 047)
|
(2 080)
|
(4 012)
|
(5 416)
|
(4 802)
|
(4 862)
|
1 226
|
3 083
|
2 394
|
1 749
|
(4 178)
|
|
| Pre-Tax Income |
38 763
N/A
|
37 293
-4%
|
92 335
+148%
|
171 567
+86%
|
230 134
+34%
|
471 128
+105%
|
448 843
-5%
|
436 294
-3%
|
362 898
-17%
|
141 733
-61%
|
83 311
-41%
|
(1 267)
N/A
|
34 179
N/A
|
7 327
-79%
|
13 187
+80%
|
25 521
+94%
|
(63 759)
N/A
|
(89 107)
-40%
|
|
| Net Income | |||||||||||||||||||
| Tax Provision |
(5 035)
|
(4 404)
|
(17 520)
|
(34 744)
|
(49 082)
|
(115 989)
|
(107 822)
|
(101 959)
|
(84 222)
|
(19 281)
|
(2 933)
|
19 543
|
11 710
|
14 990
|
9 681
|
1 914
|
20 484
|
38 990
|
|
| Income from Continuing Operations |
33 728
|
32 890
|
74 815
|
136 823
|
181 052
|
355 139
|
341 021
|
334 335
|
278 676
|
122 452
|
80 378
|
18 276
|
45 890
|
22 318
|
22 868
|
27 435
|
(43 274)
|
(50 117)
|
|
| Net Income (Common) |
33 728
N/A
|
32 890
-2%
|
74 815
+127%
|
136 823
+83%
|
181 052
+32%
|
355 139
+96%
|
341 021
-4%
|
334 335
-2%
|
278 676
-17%
|
122 452
-56%
|
80 378
-34%
|
18 276
-77%
|
45 890
+151%
|
22 318
-51%
|
22 868
+2%
|
27 435
+20%
|
(43 274)
N/A
|
(50 117)
-16%
|
|
| EPS (Diluted) |
552.91
N/A
|
530.48
-4%
|
1 168.97
+120%
|
1 782.44
+52%
|
2 392.32
+34%
|
4 810.09
+101%
|
4 427.83
-8%
|
4 341.73
-2%
|
3 618.08
-17%
|
1 589.84
-56%
|
1 046.8
-34%
|
238.01
-77%
|
597.42
+151%
|
289.79
-51%
|
297.64
+3%
|
357.09
+20%
|
-563.26
N/A
|
-649.17
-15%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
